Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ARCH.V Relative to the S&P 500

ARCH.V Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Arch Biopartners Inc (TSXV:ARCH.V) seasonal charts above shows that a Buy Date of December 20 and a Sell Date of April 15 has resulted in a geometric average return of 14.3% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 14.79% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch’s drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.

To download ARCH.V seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ARCH.V